Institution
Peking University Sixth Hospital
Also known as: School of Mental Health, Peking University
- 13running trials
- 14closed trials
- 3,410publications (OpenAlex)
Running trials
Not yet recruiting
A Study to Evaluate the Long-term Safety of HS-10380 in Patients With Schizophrenia
NCT07759869· Phase 3· Jiangsu Hansoh Pharmaceutical Co., Ltd.· Source
Recruiting
Identification and Molecular Characterisation of Urban-environmental Stress Patterns Affecting Mental Illness
NCT07571226· Huashan Hospital· Source
Recruiting
Efficacy of Bright Light Therapy on Cognitive Impairment in Major Depressive Disorder and Its Neuroimaging Mechanisms: Protocol for a Randomised Controlled Trial
NCT07508215· Peking University Sixth Hospital· Source
Recruiting
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
NCT07412756· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732· Phase 3· Bristol-Myers Squibb· Source
Recruiting
pBFS Guided aiTBS Over Language Network for ASD Child
NCT06950437· Beijing Changping Tianhe Research Institute of Brain Science· Source
Recruiting
Clinical Efficacy, Safety, and Applicability of Home-based Bright Light Therapy in Outpatient Adolescents With Major Depressive Disorder
NCT06913309· Peking University Sixth Hospital· Source
Recruiting
Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASD
NCT06757504· Phase 2· Shanghai Auzone Biological Technology Co., Ltd.· Source
Not yet recruiting
An Exploratory Clinical Study of a Low-dose Buprenorphine Patch for the Treatment of Autism Spectrum Disorders
NCT06772324· Peking University Sixth Hospital· Source
Active, not recruiting
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
NCT05531526· Phase 3· AriBio Co., Ltd.· Source
Active, not recruiting
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789· Phase 3· Eli Lilly and Company· Source
Recruiting
Study on the Mechanism of Eating Disorder
NCT05862389· Peking University· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression
NCT06827431· Phase 3· CSPC ZhongQi Pharmaceutical Technology Co., Ltd.· Source
Completed
A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD
NCT06359899· Phase 3· Shanghai Ark Biopharmaceutical Co., Ltd.· Source
Completed
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
NCT06068465· Phase 3· Tasly Pharmaceutical Group Co., Ltd· Source
Completed
A Study of Daridorexant in Chinese Patients With Insomnia Disorder
NCT06010693· Phase 3· Jiangsu Simcere Pharmaceutical Co., Ltd.· Source
Completed
A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.
NCT05970510· Phase 3· Luye Pharma Group Ltd.· Source
Completed
A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA)
NCT06103825· Phase 3· Ignis Therapeutics (Suzhou) Limited· Source
Completed
A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia
NCT05919823· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Completed
Effect of XingpiJieyu Formula on Mitochondrial Energy Metabolism in Severe Liver-Stagnation and Spleen-Deficiency Depression.
NCT07590609· Phase 4· Peking University Sixth Hospital· Source
Completed
Software-delivered CBT-I for Insomnia Disorder
NCT05747963· Peking University Sixth Hospital· Source
Completed
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
NCT05550532· Phase 3· Janssen Research & Development, LLC· Source
Completed
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)
NCT04846868· Phase 3· Boehringer Ingelheim· Source
Completed
A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder
NCT04693351· Phase 3· Biohaven Pharmaceuticals, Inc.· Source
Completed
RCT Study on the Therapeutic Effect of Escitalopram Loaded With XingpiJieyu Formula on Resting State EEG Energy Abnormalities in Severe Liver Depression and Spleen Deficiency Type MDD
NCT06758167· Peking University Sixth Hospital· Source
Completed
Effectiveness of eCBT-I on Improving Mental Health in Chinese Youths With Insomnia
NCT04069247· Chinese University of Hong Kong· Source
Registry name variants (3)
Show allHide
Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.
Peking University Sixth Hospital
Beijing, 100083
23 trials
Peking University Sixth Hospital
Haidian District, 100191
3 trials
Institute of Mental Health, Peking University Sixth Hospital
Beijing
1 trial
Conditions
Diseases this institution publishes on or runs trials for.
Report an error